ASND Earnings Prediction
The chart below shows how ASND performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ASND sees a -1.30% change in stock price 10 days leading up to the earnings, and a +5.58% change 10 days following the report. On the earnings day itself, the stock moves by +0.50%. This data can give you a slight idea of what to expect for the next quarter's release.
ASND Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
ASND Earnings Analysis
Ascendis Pharma A/S Corporation (ASND.O) Earnings Conference Call
Positive
Skytrofa Revenue and Market Share: Skytrofa revenue reached approximately EUR 200 million in 2024, capturing a 6.5% market share of the total growth hormone market in the U.S. and around 45% of the long-acting growth hormone market.
Strong Revenue Performance: YorvaPath generated EUR 13.6 million in revenue for Q4 2024, contributing to a total of EUR 28.7 million for the full year, with strong early demand and positive reimbursement progress in the U.S.
Cash Position and Investment Potential: Ascendis Pharma ended 2024 with cash and cash equivalents totaling EUR 665 million, bolstered by a $100 million upfront payment from Novo Nordisk, positioning the company for continued investment in growth and development.
Skytrofa Volume Surge: Skytrofa volume increased by 84% in 2024, with premium net pricing three times that of daily growth hormone, indicating strong market acceptance and potential for future growth.
TransCon CMP Clinical Trial Success: TransCon CMP demonstrated significant improvements in linear growth and body proportionality in clinical trials, supporting its potential as a best-in-class treatment for achondroplasia, with NDA submission planned for Q1 2025.
Negative
Revenue Decline Despite Volume Increase: Skytrofa revenue decreased to EUR 58.5 million in Q4 2024 from EUR 64.2 million in Q4 2023, indicating a decline in financial performance despite a 37% increase in volume.
Operating Expenses Increase: Total operating expenses for Q4 2024 rose to EUR 159.5 million, a 3% increase from EUR 154.9 million in Q4 2023, reflecting rising costs despite revenue challenges.
R&D Cost Reduction Insights: R&D costs decreased by 13% in Q4 2024, but this was primarily due to lower external development costs, suggesting potential setbacks in product development initiatives.
Net Finance Expenses Analysis: Net finance expenses for the full year 2024 were EUR 74.4 million, primarily driven by non-cash items, indicating financial strain despite a strong cash position.
Treasury Shares Preservation: The company expects to use approximately $25 million in Q1 2025 to preserve around 200,000 ADS held as treasury shares, indicating potential liquidity concerns.
ASND FAQs
How does ASND typically perform around its earnings report dates?
Is Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ASND Earning Call Sentiment
Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise
ASND.O
0.44%Positive
The earnings call reveals several positive factors: a partnership with Novo Nordisk, significant revenue guidance for SKYTROFA, and strong early demand for YORVIPATH. Despite a drop in Skytrofa revenue due to sales deductions, volume growth is strong, and the cash position is robust. The Q&A section highlights a positive outlook on growth opportunities and reimbursement. The strategic partnership and optimistic guidance outweigh the concerns about pricing pressures and insurance delays, suggesting a positive short-term stock price movement.
